Breaking News
ViGeneron Rebrands as VeonGen, Earns FDA RPDD for Gene Therapy

VeonGen Therapeutics has officially announced its rebranding from ViGeneron, marking a strategic tra...

read more
ViGeneron Rebrands as VeonGen, Earns FDA RPDD for Gene Therapy
June 16, 2025
FDA Approves Amneal’s Prednisolone Acetate Ophthalmic Suspension for Steroid-Responsive Ocular Inflammation

Amneal Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved i...

read more
FDA Approves Amneal’s Prednisolone Acetate Ophthalmic Suspension for Steroid-Responsive Ocular Inflammation
June 13, 2025
European Commission Approves Ryjunea for Slowing Progression of Pediatric Myopia

The European Commission (EC) has granted marketing authorization for Ryjunea (SYD-101), Sydnexis’ pr...

read more
European Commission Approves Ryjunea for Slowing Progression of Pediatric Myopia
June 10, 2025
FDA Accepts NDA for Brimochol PF to Treat Presbyopia

The U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) f...

read more
FDA Accepts NDA for Brimochol PF to Treat Presbyopia
June 04, 2025
Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease

Alcon has received U.S. FDA approval for Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly k...

read more
Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease
May 30, 2025
FDA Approves Genentech’s Susvimo for the Treatment of Diabetic Retinopathy

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranib...

read more
FDA Approves Genentech’s Susvimo for the Treatment of Diabetic Retinopathy
May 23, 2025
Grifols Receives FDA Clearance to Begin Phase 2 Trial of Immunoglobulin Eye Drops for Dry Eye Disease

Grifols has announced FDA clearance of its Investigational New Drug (IND) application, allowing the ...

read more
Grifols Receives FDA Clearance to Begin Phase 2 Trial of Immunoglobulin Eye Drops for Dry Eye Disease
May 22, 2025
FDA Grants Breakthrough Therapy Designation to Tinlarebant for Stargardt Disease

Belite Bio has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough T...

read more
FDA Grants Breakthrough Therapy Designation to Tinlarebant for Stargardt Disease
May 22, 2025
FDA Approves Atia Vision to Initiate U.S. Clinical Trial for OmniVu Lens System in Cataract Patients

Atia Vision has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...

read more
FDA Approves Atia Vision to Initiate U.S. Clinical Trial for OmniVu Lens System in Cataract Patients
May 21, 2025
Intalight Secures CE Mark for DREAM OCT Platform, Clears Path for Commercialization in Europe

Intalight has announced that it has received CE Mark approval for its next-generation DREAM OCT plat...

read more
Intalight Secures CE Mark for DREAM OCT Platform, Clears Path for Commercialization in Europe
May 16, 2025
More